- CH₣240.95bn
- CH₣273.64bn
- $56.33bn
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Brief: Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies
Nuvectis gains two experimental drugs in licensing deal with China's Haisco (updated)
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Table: Swiss trade surplus at CHF 6.11 bln in May
Factbox: Global drugmakers invest billions to boost US presence
Brief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'
Brief: Novartis Delpacibart Braxlosiran Phase I/II Study In Facioscapulohumeral Muscular Dystrophy Meets Primary Biomarker Endpoint
Analysis: Businesses fear for economy if Swiss vote to cap population at 10 million
Swiss firms invest $27 billion in US after tariff deal, NZZ am Sonntag reports
Celcuity rises after boosted $500 mln convertible bond offering
Swiss stocks - Factors to watch on June 4
Brief: Novartis Cosentyx® Pmr Data In New England Journal Of Medicine Showed Sustained Remission Versus Placebo In Twice As Many Patients
Celcuity drops further after announcing $400 mln convertible offering